ArticleInternational journal of nanomedicine2018
Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 74 citations in OpenAlex.
- Synthesis and Biological Properties of Isatin-indole Hybrids: A Review.Mini reviews in medicinal chemistry · 2025Review
- Optimization of Polylactide-Co-Glycolide-Rifampicin Nanoparticle Synthesis, In Vitro Study of Mucoadhesion and Drug Release.Polymers · 2024Article
- Drug-loaded polymer-coated silver nanoparticles for lung cancer theranostics.Medical oncology (Northwood, London, England) · 2024Article
- Poly-Gamma-Glutamic Acid Nanopolymer Effect against Bacterial Biofilms: In Vitro and In Vivo Study.Biomedicines · 2024Article
- Evaluating the Sensitivity of Different Molecular Techniques for DetectingPolish journal of microbiology · 2023Article
- Nanocarriers in Tuberculosis Treatment: Challenges and Delivery Strategies.Pharmaceuticals (Basel, Switzerland) · 2023Review
- In Vivo Toxicity, Redox-Modulating Capacity and Intestinal Permeability of Novel Aroylhydrazone Derivatives as Anti-Tuberculosis Agents.Pharmaceutics · 2022Article
- Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Development of a novel anti-tuberculosis nanodelivery formulation using magnesium layered hydroxide as the nanocarrier and pyrazinamide as a model drug.Scientific reports · 2022Article
- Article
- Photoclick Reaction Constructs Glutathione-Responsive Theranostic System for Anti-Tuberculosis.Frontiers in molecular biosciences · 2022Article
- Nanoparticle-Based Inhalation Therapy for Pulmonary Diseases.Current drug metabolism · 2022Article
- Nanoparticle-Based Rifampicin Delivery System Development.Molecules (Basel, Switzerland) · 2021Article
- A Novel Para-Amino Salicylic Acid Magnesium Layered Hydroxide Nanocomposite Anti-Tuberculosis Drug Delivery System with Enhanced in vitro Therapeutic and Anti-Inflammatory Properties.International journal of nanomedicine · 2021Article
- Mycogenic Metal Nanoparticles for the Treatment of Mycobacterioses.Antibiotics (Basel, Switzerland) · 2020Review
- Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections.Molecules (Basel, Switzerland) · 2020Review
- Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.Drug delivery and translational research · 2020Review
- A synergistic bactericidal effect of low-frequency and low-intensity ultrasound combined with levofloxacin-loaded PLGA nanoparticles on M. smegmatis in macrophages.Journal of nanobiotechnology · 2020Article
- In Vivo Biodistribution of Respirable Solid Lipid Nanoparticles Surface-Decorated with a Mannose-Based Surfactant: A Promising Tool for Pulmonary Tuberculosis Treatment?Nanomaterials (Basel, Switzerland) · 2020Article
- The Impact of Lipid Corona on Rifampicin Intramacrophagic Transport Using Inhaled Solid Lipid Nanoparticles Surface-Decorated with a Mannosylated Surfactant.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTuberculosis (TB) is the single largest infectious disease which requires a prolonged treatment regime with multiple drugs. The present treatment for TB includes frequent administration of a combination of four drugs for a duration of 6 months. This leads to patient's noncompliance, in addition to developing drug-resistant strains which makes treatment more difficult. The formulation of drugs with biodegradable polymeric nanoparticles (NPs) promises to overcome this problem. MATERIALS AND
methodsIn this study, we focus on two important drugs used for TB treatment - rifampicin (RIF) and isoniazid (INH) - and report a detailed study of RIF-loaded poly lactic-co-glycolic acid (PLGA) NPs and INH modified as INH benz-hydrazone (IH2) which gives the same therapeutic effect as INH but is more stable and enhances the drug loading in PLGA NPs by 15-fold compared to INH. The optimized formulation was characterized using particle size analyzer, scanning electron microscopy and transmission electron microscopy. The drug release from NPs and stability of drug were tested in different pH conditions.
resultsIt was found that RIF and IH2 loaded in NPs release in a slow and sustained manner over a period of 1 month and they are more stable in NPs formulation compared to the free form. RIF- and IH2-loaded NPs were tested for antimicrobial susceptibility against
conclusionThese results show that NP formulations will improve the efficacy of drug delivery for TB treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.